CA2045071A1 - Acellular anti-pertussis vaccines - Google Patents

Acellular anti-pertussis vaccines

Info

Publication number
CA2045071A1
CA2045071A1 CA002045071A CA2045071A CA2045071A1 CA 2045071 A1 CA2045071 A1 CA 2045071A1 CA 002045071 A CA002045071 A CA 002045071A CA 2045071 A CA2045071 A CA 2045071A CA 2045071 A1 CA2045071 A1 CA 2045071A1
Authority
CA
Canada
Prior art keywords
pertussis
amino acid
fha
vaccines
subunit
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002045071A
Other languages
English (en)
French (fr)
Inventor
Luciano Nencioni
Massimo Bugnoli
Roberto Manetti
Ilio Marsili
Paolo Ruggiero
Rino Rappuoli
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GSK Vaccines SRL
Original Assignee
Sclavo SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=11170908&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2045071(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sclavo SpA filed Critical Sclavo SpA
Publication of CA2045071A1 publication Critical patent/CA2045071A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/235—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bordetella (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
    • A61K39/0018—Combination vaccines based on acellular diphtheria-tetanus-pertussis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA002045071A 1990-06-21 1991-06-20 Acellular anti-pertussis vaccines Abandoned CA2045071A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT02071090A IT1248735B (it) 1990-06-21 1990-06-21 Vaccini acellulari contro la pertosse
IT20710 1990-06-21

Publications (1)

Publication Number Publication Date
CA2045071A1 true CA2045071A1 (en) 1991-12-22

Family

ID=11170908

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002045071A Abandoned CA2045071A1 (en) 1990-06-21 1991-06-20 Acellular anti-pertussis vaccines

Country Status (4)

Country Link
EP (1) EP0462534A3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JP2690215B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2045071A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IT (1) IT1248735B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8412207D0 (en) * 1984-05-12 1984-06-20 Wellcome Found Antigenic preparations
GB8910570D0 (en) 1989-05-08 1989-06-21 Wellcome Found Acellular vaccine
EP0484621A3 (en) * 1990-07-11 1992-08-26 American Cyanamid Company Efficacious vaccines against bordetella pertussis comprising a combination of individually purified pertussis antigens
GB9513371D0 (en) 1995-06-30 1995-09-06 Biocine Spa Immunogenic detoxified mutant toxins
GB9209118D0 (en) * 1992-04-28 1992-06-10 Sb 120 Amsterdam Bv Vaccine compositions
US5856122A (en) * 1993-08-24 1999-01-05 University Of Alberta Modification of pertussis toxin
WO1995009649A1 (en) 1993-10-05 1995-04-13 Medeva Holdings B.V. Vaccine compositions
GB9326174D0 (en) 1993-12-22 1994-02-23 Biocine Sclavo Mucosal adjuvant
JP5148577B2 (ja) * 1993-12-22 2013-02-20 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル 非毒性の粘膜アジュバント
US6051240A (en) * 1994-04-28 2000-04-18 Takeda Chemical Industries, Ltd. Method of separating protective components of Bordetella pertussis
US20030072774A1 (en) * 1994-06-10 2003-04-17 Diane M. Gajewczyk Proteinaceous adjuvants
GB9500788D0 (en) * 1995-01-16 1995-03-08 Medeva Holdings Bv Vaccine compositions
GB9622660D0 (en) 1996-10-31 1997-01-08 Biocine Spa Immunogenic detoxified mutant toxin
US6818222B1 (en) 1997-03-21 2004-11-16 Chiron Corporation Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants
GB9713156D0 (en) * 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines
RU2130778C1 (ru) * 1998-07-31 1999-05-27 Акционерное общество закрытого типа НПК "Комбиотех Лтд" Комбинированная вакцина для иммунопрофилактики вирусного гепатита в, столбняка, дифтерии и коклюша
US7115730B1 (en) 1999-04-27 2006-10-03 Chiron Srl Immunogenic detoxified mutant E. coli LT-A-toxin
GB9923060D0 (en) * 1999-09-29 1999-12-01 Chiron Spa Vaccine
WO2010131111A1 (en) 2009-05-11 2010-11-18 Novartis Ag Antigen purification process for pertactin antigen
AU2013229432A1 (en) 2012-03-08 2014-10-16 Novartis Ag Adjuvanted formulations of booster vaccines

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6176422A (ja) * 1984-09-22 1986-04-18 Chemo Sero Therapeut Res Inst 百日ぜきコンポ−ネントワクチンおよび百日ぜき・ジフテリア・破傷風混合ワクチンの製造方法
IT1223334B (it) * 1987-11-02 1990-09-19 Sclavo Spa Polipeptidi immunologicamente attivi con una tossicita' alterata utili per la preparazione di un vaccino antipertosse
AP8900132A0 (en) * 1988-07-22 1991-01-14 Smithkline Biolog Bordetella pertussis vaccine
DK0396964T3 (da) * 1989-04-28 1995-10-30 Sclavo Spa Pertussistoxin-mutanter, Bordetella-stammer, der er i stand til at producere sådanne mutanter, samt deres anvendelse til udvikling af antipertussis-vacciner
CA2069622A1 (en) * 1989-11-29 1991-05-30 Camille Locht Vaccine

Also Published As

Publication number Publication date
IT9020710A0 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1990-06-21
IT9020710A1 (it) 1991-12-21
JPH04368337A (ja) 1992-12-21
IT1248735B (it) 1995-01-26
EP0462534A2 (en) 1991-12-27
EP0462534A3 (en) 1992-12-02
JP2690215B2 (ja) 1997-12-10

Similar Documents

Publication Publication Date Title
EP0462534A2 (en) Acellular anti-pertussis vaccines
AU714493B2 (en) Multivalent DTP-polio vaccines
US7427404B1 (en) Pertussis toxin mutants, bordetella strains capable of producing such mutants and their use in the development of antipertussis vaccines
EP1233022B1 (en) Methods of preparation of components of acellular pertussis vaccines
US6696065B1 (en) Acellular pertussis vaccines and methods of preparation thereof
US5877298A (en) Acellular pertussis vaccines and methods of preparing thereof
HK1004524B (en) Novel vaccine and method therefor
EP0352250B1 (en) Bordetella pertussis vaccine
EP0550683B1 (en) Vaccine suitable for combatting bordetella pertussis
HK1004568B (en) Bordetella pertussis vaccine
Burnette et al. Properties of pertussis toxin B oligomer assembled in vitro from recombinant polypeptides produced by Escherichia coli
DE69028785T2 (de) Neuer impfstoff
PIZZA et al. Construction of genetically detoxified pertussis toxin
MXPA99000184A (es) Vacunas multivalentes de dtp-polio

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued